VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis [Yahoo! Finance]
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Yahoo! Finance
VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis. Shares of the company were down 6.1% on Sept. 19 following the announcement of the news. Marked by delayed gastric emptying, gastroparesis is a serious condition that slows down the stomach's ability to empty its contents. The FDA has not approved any effective medicine for treating gastroparesis in more than 40 years. Year to date, shares of Vanda have increased 10.2% compared with the industry's rise of 0.4%. Image Source: Zacks Investment Research More on FDA's CRL for VNDA's Tradipitant Per the CRL, the FDA called for Vanda to conduct additional studies on tradipitant with a design that was inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding of the disease. Also, per management, the FDA delayed its dec
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- Here's Why You Should Invest in Illumina (ILMN) [Yahoo! Finance]Yahoo! Finance
- Minimal Residual Disease Testing Market Worth $4.45 billion by 2031--Exclusive Report by Meticulous Research® [Yahoo! Finance]Yahoo! Finance
- Decoding Illumina Inc (ILMN): A Strategic SWOT Insight [Yahoo! Finance]Yahoo! Finance
- Illumina To Webcast Upcoming Investor ConferencesPR Newswire
- Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Robert W. Baird from $124.00 to $139.00. They now have a "neutral" rating on the stock.MarketBeat
ILMN
Earnings
- 11/4/24 - Beat
ILMN
Sec Filings
- 11/7/24 - Form 4
- 11/7/24 - Form 4
- 11/7/24 - Form 4
- ILMN's page on the SEC website